Translumina acquires Blue Medical Devices

Translumina and Everstone’s Senior management team with Shareholders of Blue Medical Devices, a Wellinq Group Company

Translumina has announced the acquisition of Blue Medical Devices, a Wellinq group company, based out of Helmond, The Netherlands. The company, incorporated in 2013, produces an innovative basket of balloon catheters including drug coated balloons (DCB) and other speciality balloons for complex coronary interventions, Translumina said in a press release.

Wellinq’s CEO, Sander Hartman, stated: “Becoming part of Translumina, which is an emerging front runner in building a great product- and technology portfolio in coronary and structural heart interventions across the world, marks the beginning of an exciting new chapter for Blue Medical. We are convinced that Blue Medical’s next-generation Drug Coated Balloon catheters have a tremendous market opportunity with the global sales and marketing network of Wellinq’s long term partner Translumina.”

“This acquisition is of strategic importance as it complements our next generation drug-eluting stents portfolio to offer a complete solution for all coronary interventions. Drug coated balloons are gaining huge significance in treating certain complex lesion subsets and I am confident that this unique technology will provide new treatment possibilities for physicians and patients worldwide,” said Gurmit Singh Chugh who, along with Punita Sharma, founded Translumina in 2010.

Drug-eluting balloons are now being considered a treatment of choice for in-stent restenosis, smaller vessels, bifurcations and multivessel disease. Current estimates project the DCB market to be almost 30% of the global DES market in the next five years, Translumina said in its press release.

“I am excited to lead Translumina in this new wave of creating global leadership with path breaking technologies. Our German lineage now makes further inroads in Europe with this move to Netherlands, enabling us to offer a broad range of therapy solutions and disruptive innovations that address the unmet patient needs,” said Indranil Mukherjee, Group CEO, Global Business.

The acquisition shall also enable Translumina to use the patented drug application technology of Blue Medical in other product lines in peripheral and neurovascular interventions complimenting its leadership in unique and innovative dug coating recipes.

The acquisition of Blue Medical Devices comes shortly after Translumina announced the acquisition of Munich-based Lamed GmbH.


Please enter your comment!
Please enter your name here